高血管风险人群中ACEI与ARB的疗效比较
该观察性研究纳入高危心血管风险患者40625例(ACEI 67.9%,ARB 32.1%),比较两类药物4年主要心血管事件发生率。倾向评分校正后,ARB组主要结局发生率低于ACEI组(29.2% vs 33.4%;校正HR 0.90;95%CI 0.86至0.95;p<0.001)。作者认为ARB可能与心血管事件率降低10%相关,尤其在已确诊心血管疾病患者中。
要点
- 倾向评分校正后ARB组主要结局发生率低于ACEI组(29.2% vs 33.4%;校正HR 0.90;95%CI 0.86至0.95;p<0.001)。
- ARB组心血管死亡(6.9% vs 8.2%;HR 0.83;95%CI 0.75至0.93;p=0.001)和全因死亡(11.6% vs 12.6%;HR 0.89;95%CI 0.82至0.97;p=0.005)均低于ACEI组。
- ARB与较低全因死亡率的相关性见于二级预防患者而非一级预防患者(交互作用p=0.03)。
核心结论
- 在高血管风险人群中,ARB使用似乎与较ACEI低10%的心血管事件率相关,尤其在已确诊心血管疾病患者中。
- 作者认为,在真实世界实践的高危患者中,ARB可能较ACEI提供更优的心血管事件保护。
研究设计与样本
- 减少动脉粥样硬化血栓形成以维持健康注册研究为观察性研究,纳入69055例高心血管风险个体,其中40625例患者纳入分析(ACEI 67.9%,ARB 32.1%)。
- 主要结局为4年心血管死亡、非致死性心肌梗死、非致死性卒中或心血管疾病住院的发生率。
主要发现
- 倾向评分校正队列中,ARB组主要结局发生率低于ACEI组(29.2% vs 33.4%;校正HR 0.90;95%CI 0.86至0.95;p<0.001)。
- 心血管死亡(6.9% vs 8.2%;HR 0.83;95%CI 0.75至0.93;p=0.001)与全因死亡(11.6% vs 12.6%;HR 0.89;95%CI 0.82至0.97;p=0.005)在ARB组均低于ACEI组。
- 倾向评分匹配分析结果相似。
- 糖尿病史或估算肾小球滤过率未影响结果。
- ARB使用与较低全因死亡率在二级预防中相关,但在一级预防患者中不相关(交互作用p=0.03)。
临床怎么用
- 原文未据此给出推荐,仅报告ARB使用似乎与较低心血管事件率相关,尤见于已确诊心血管疾病患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are widely prescribed in patients with high cardiovascular (CV) risk. However, whether both classes have equivalent effectiveness to prevent CV events remains unclear. The aim of this study was to compare the incidence of major CV events between ACEI and ARB users. METHODS: The Reduction of Atherothrombosis for Continued Health registry is an observational study who enrolled 69 055 individuals with high CV risk. Among them, 40 625 patients (ACEIs 67.9% and ARBs 32.1%) were included. Main outcome was rates of CV mortality, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for CV disease at 4 years. RESULTS: In a propensity score-adjusted cohort, the incidence of the primary outcome was lower in patients on ARBs compared with ACEIs (29.2% vs 33.4%; adjusted HR 0.90; 95% CI 0.86 to 0.95; p<0.001). Similar results were observed for CV (6.9% vs 8.2%; HR 0.83; 95% CI 0.75 to 0.93; p=0.001) and all-cause mortality (11.6% vs 12.6%; HR 0.89; 95% CI 0.82 to 0.97; p=0.005). Analyses using propensity score matching yielded similar results. History of diabetes or estimated glomerular filtration rate did not affect the results. ARB use was associated with lower rates of all-cause mortality in secondary prevention but not in primary prevention patients (p-value for interaction=0.03). CONCLUSION: ARB use appears to be associated with 10% lower rates of CV events compared with ACEIs, especially in patients with established CV disease. Our results suggest that ARBs may provide superior protection against CV events than ACEIs in high-risk patients in real-world practice.
引用
- Potier L, Roussel R, Elbez Y, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 2017. PMID: 28285267. doi:10.1136/heartjnl-2016-310705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。